A Novel Pregelatinized Starch as a Sustained-Release Matrix Excipient - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Novel Pregelatinized Starch as a Sustained-Release Matrix Excipient
The authors examine the use of a novel highly functional pregelatinized starch as a controlled-release matrix excipient.


Pharmaceutical Technology



Figure 8
Figure 8 shows the change of tablet weight (see Figure 8a) and water-absorbing capacity (see Figure 8b). The water-absorbing capacity was calculated as a percentage by comparing the tablet weight in the wet state due to water absorption with the tablet weight in the dry state after drying. During 0–2 h, these matrix tablets absorbed a lot of water, and their weights increased. After 2 h, the weights of matrix tablets began to decrease in spite of keeping water absorption. The HS tablet with PEG remarkably absorbed water and lost its weight because the strength of its gel structure weakened.


Figure 9
Figure 9 is a schematic description of the assumed mechanism of different actions between HS and HPMC matrix tablets caused by promotion of water penetration into tablets by adding PEG. In the case of HS, in the first stage at 0.5–5 h, the hydration of HS particles was promoted, and a strong gel layer was formed, which contributed to the restraint of drug diffusion. In the second stage of 6 h and after, excess water absorption occurred because the HS water-insoluble elements absorbed a lot of water without dissolving, which contributed to decrease gel strength and to promote gel erosion. Accordingly, the drug-release profiles inclined to zero-order release. In the case of HPMC, the hydration rate of the HPMC particles was not largely affected by adding PEG because the hydration rate was originally rapid. Therefore, the drug-release profiles remained first order regardless of adding PEG.


Table 3
Storage stability study of dissolution profiles and of tablets color. HS or HPMC matrix tablets containing APAP and MCC with or without PEG were used in this study. Table III shows the formulations of the tablets. These tablets were stored at 40 C and 75% RH in sealed glass bottles and at 60 C in polyamine–polyethylene bags.


Figure 11
Figure 10 shows the dissolution profiles at the initial state and after storage for 6 months. The dissolution tests were performed using a USP Type 1 apparatus at a rotation speed of 100 rpm in a JP-2 buffer containing α-amylase in a 5-g/L concentration. For HS matrix tablets, no significant change in release profiles was observed. In contrast, those of HPMC changed under the same conditions.


Figure 12
Figure 11 shows the change of YI. Under conditions of 40 C and 75 % RH, the YI of the HS matrix tablets slightly changed, although that of HPMC remarkably increased. At 60 C, the YI of both increased, but the YI of the HS matrix tablets after 6 months was the same level with the initial YI of HPMC tablets. In addition, the YI of the HPMC matrix with PEG remarkably increased.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here